Exploring New Models for Treating Low-Income Cancer Patients in Hong Kong—Dr. Cheng Kam-chung, JP, and Delegation Visit Shenzhen Cell Valley for Exchange

On May 31, Dr. Cheng Kam-chung, a renowned philanthropist, Justice of the Peace, Chairman of the Environment and Conservation Fund Committee, former Chairman of the Po Leung Kuk, and recipient of the Silver Bauhinia Star and the Medal of Honour, along with Dr. Shao Zude, Fellow of the Royal College of Physicians, former Chairman of the Department of Clinical Oncology at the University of Hong Kong, and their delegation, visited Shenzhen Cell Valley for exchange and discussion. Our Chairman, Shi Yuanyuan; Deputy General Manager, Tang Xiaomeng; Head of Marketing, Sun Rui; and Director of the General Administration Office, Luan Zhishi, extended a warm welcome to the delegation.

First, accompanied by Chairman Shi Yuanyuan, the visiting guests toured the smart exhibition hall, R&D laboratories, production and quality control workshops, gaining an initial understanding of Shenzhen Cell Valley's full-industry-chain layout in the cell and gene therapy field, development history, core team, production scale, R&D capabilities, and quality management system.

During the symposium, Chairman Shi Yuanyuan expressed sincere gratitude to the visiting guests and provided a detailed introduction to Shenzhen Cell Valley's core innovative technologies with independent intellectual property rights and clinical treatment cases. Chairman Shi stated that the Cell Valley team, adhering to the mission of "Cells benefit all, genes create the future," has leveraged its strong R&D capabilities to prepare CAR-T cells under a rigorous production quality management system, benefiting dozens of patients with hematologic malignancies, and has provided cell preparation services free of charge on multiple occasions. Recent major breakthroughs in the preparation of high-purity NK cells and CAR-NK cells have opened up technological possibilities for breaking through solid tumors and various refractory chronic diseases such as Alzheimer's and Parkinson's disease.

Chairman Cheng Kam-chung highly praised the excellent therapeutic outcomes achieved by Shenzhen Cell Valley in immune cell clinical therapy and the philosophy of "Cells benefit all." He noted that the establishment of Shenzhen Cell Valley provides an ideal platform for accelerating the clinical application of cutting-edge cell therapy technologies and reducing treatment costs. He expressed the hope that, through Hong Kong charitable and public welfare projects and relevant Shenzhen-Hong Kong policies, while jointly promoting the development of cell therapy in the Guangdong-Hong Kong-Macao Greater Bay Area, a linkage could be established between Hong Kong charitable foundations, Shenzhen Cell Valley, and Shenzhen medical institutions to explore a new support mechanism for providing cutting-edge cellular immunotherapy to low-income cancer patients in Hong Kong. Dr. Shao Zude noted that immune cell therapy offers a completely new treatment approach for diseases that cannot be addressed by traditional medical methods, with broad market prospects and social value. Shenzhen-Hong Kong cooperation will deeply promote the integrated development of related technologies and provide high-quality medical services to more cancer patients.

Both parties expressed their commitment to integrating their respective resources and working together to contribute to the charitable cause of treating low-income cancer patients in Hong Kong.